These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2123370)

  • 1. Two-year carbohydrate metabolism studies in women using a norethindrone or levonorgestrel triphasic oral contraceptive.
    Spellacy WN; Ellingson AB; Tsibris JC
    Adv Contracept; 1990 Sep; 6(3):185-91. PubMed ID: 2123370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
    Spellacy WN; Ellingson AB; Tsibris JC
    Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
    Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
    Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate metabolic studies in women using a levonorgestrel/ethinyl estradiol containing triphasic oral contraceptive for eighteen months.
    Spellacy WN; Tsibris JC; Ellingson AB
    Int J Gynaecol Obstet; 1991 May; 35(1):69-71. PubMed ID: 1680079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of combined oral contraceptive preparations.
    Singh BM; Nutter SA; Nattrass M
    Contraception; 1987 Dec; 36(6):651-8. PubMed ID: 3128428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
    Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
    Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors.
    Skouby SO; Wagner HH; Andersen O
    Contraception; 1983 Nov; 28(5):489-99. PubMed ID: 6425010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of carbohydrate metabolism in women using a triphasic oral contraceptive containing norethindrone and ethinyl estradiol for 3 months.
    Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
    Am J Obstet Gynecol; 1988 Oct; 159(4):877-9. PubMed ID: 3052079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
    Masson S; Franssen E; Hilditch JR; Powell MG
    Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose and insulin levels after six months of treatment with a triphasic oral contraceptive containing ethinyl estradiol and norethindrone.
    Spellacy WN; Ellingson AB; Tsibris JC
    J Reprod Med; 1989 Aug; 34(8):540-2. PubMed ID: 2681750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
    Wilson ES; Cruickshank J; McMaster M; Weir RJ
    Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
    Spellacy WN
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.